Today's Low
₹ 71.00
Today's High
₹ 72.85
52 Weeks Low
₹ 50.65
52 Weeks High
₹ 145.90
Lower
₹ 65.70
Upper
₹ 80.30
Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione, lovastatin, and simvastatin for anti-cholesterol and steroid intermediate applications. The company is also developing various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is headquartered in Hyderabad, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 35.5 | 21.4 | 18.9 | 31.0 | 17.2 | 13.0 | 9.4 | 14.9 | 38.8 | 38.4 | 43.0 |
Total Non-Current Assets | 154.3 | 137.8 | 114.9 | 111.4 | 108.6 | 109.1 | 107.0 | 92.3 | 97.7 | 97.5 | 104.6 |
Total Assets | 189.8 | 159.2 | 133.8 | 142.4 | 125.9 | 122.1 | 116.4 | 107.1 | 136.5 | 135.9 | 147.6 |
Total Current Liabilities | 78.1 | 48.2 | 43.1 | 54.9 | 42.3 | 31.7 | 29.5 | 28.7 | 109.8 | 70.6 | 58.9 |
Total Non-Current Liabilities | 186.8 | 153.8 | 115.7 | 101.8 | 101.4 | 88.9 | 73.9 | 60.1 | 23.0 | 57.3 | 65.5 |
Shareholder's Funds | -75.1 | -42.7 | -25.0 | -14.3 | -17.8 | 1.5 | 13.0 | 18.3 | 3.6 | 8.0 | 23.2 |
Total Liabilities | 189.8 | 159.2 | 133.8 | 142.4 | 125.9 | 122.1 | 116.4 | 107.1 | 136.5 | 135.9 | 147.6 |
The Industry Debt to Equity Ratio stands at 0.20, vs the Debt to Equity Ratio of -1.84, which results in a Positive aspect.
The Industry Current Ratio stands at 2.54, vs the Current Ratio of 0.33, which results in a Negative aspect.
The Industry Price to BV stands at 6.28, vs the Price to BV of -1.39, which results in a Negative aspect.
The Industry Quick Ratio stands at 1.77, vs the Quick Ratio of 0.08, which results in a Negative aspect.
Particulars | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 59.7 | 53.7 | 33.4 | 47.8 | 33.8 | 3.5 | 1.3 | 0.0 | 0.0 | 11.5 | 70.8 |
Total Expenditure | 93.6 | 71.3 | 52.0 | 57.5 | 41.3 | 11.5 | 13.7 | 4.9 | 4.0 | 24.6 | 74.5 |
Operating Profit(Excl OI) | -32.8 | -17.0 | -18.2 | -9.4 | -7.3 | -7.9 | -11.4 | -4.9 | -3.9 | -7.0 | -1.0 |
Add: Other Income | 1.2 | 0.6 | 0.4 | 0.3 | 0.2 | 0.1 | 1.0 | 0.0 | 0.2 | 6.1 | 2.8 |
Operating Profit | -32.8 | -17.0 | -18.2 | -9.4 | -7.3 | -7.9 | -11.4 | -4.9 | -3.9 | -7.0 | -1.0 |
Less: Interest | 5.5 | 6.3 | 6.0 | 6.3 | 5.2 | 3.5 | 0.7 | 4.0 | 0.1 | 0.6 | 8.7 |
PBDT | -38.2 | -23.2 | -24.2 | -15.7 | -12.5 | -11.4 | -12.1 | -8.9 | -4.0 | -7.7 | -9.7 |
Less: Depreciation Amortization | 6.3 | 5.1 | 4.7 | 4.4 | 4.2 | 4.2 | 4.5 | 1.9 | 0.0 | 8.3 | 9.7 |
PBT & Exceptional Items | -44.5 | -28.4 | -28.9 | -20.1 | -16.6 | -15.7 | -16.6 | -10.8 | -4.0 | -15.9 | -19.3 |
Less: Exceptional Income Expenses | 0.0 | 0.0 | 0.0 | 0.1 | -1.2 | -0.4 | 0.3 | 3.0 | 0.0 | 0.0 | 0.0 |
Profit Before Tax | -44.5 | -28.4 | -28.9 | -20.0 | -17.8 | -16.1 | -16.3 | -7.8 | -4.0 | -15.9 | -19.3 |
Less: Taxation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | -0.7 | -1.9 |
Profit After Tax | -44.5 | -28.4 | -28.9 | -20.0 | -17.8 | -16.1 | -16.3 | -7.8 | -4.4 | -15.2 | -17.4 |
Earnings Per Share | -0.2 | -0.1 | -0.2 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | 0.0 | -0.2 | -0.2 |
The Industry PAT Growth stands at 39.83, vs the PAT Growth of 44.55, which results in a Positive aspect.
The Industry Dividend Yield stands at 0.57, vs the Dividend Yield of 0.00, which results in a Negative aspect.
The Industry PE Ratio stands at 44.23, vs the PE Ratio of 0.00, which results in a Negative aspect.
The Industry PAT Margin stands at 9.70, vs the PAT Margin of -47.36, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | -24.7 | -44.5 | -28.4 | -28.9 | -20.1 | -16.6 | -16.0 | -16.6 | -10.8 | -4.1 | -15.9 | -19.3 |
Tax Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -0.1 |
Adjustment | 9.8 | 11.4 | 11.7 | 9.0 | 10.3 | 6.5 | 10.7 | 3.5 | 8.8 | 0.2 | 2.8 | 15.6 |
Changes In Working Capital | -24.7 | -44.5 | -28.4 | -28.9 | -20.1 | -16.6 | -16.0 | -16.6 | -10.8 | -4.1 | -15.9 | -19.3 |
Cash Flow after changes in Working Capital | -24.7 | -17.2 | -14.6 | -35.5 | 3.9 | -1.0 | -7.7 | -14.5 | -41.2 | 50.8 | -0.8 | 16.0 |
Cash Flow from Operating Activities | -24.7 | -17.2 | -14.6 | -35.5 | 3.9 | -6.2 | -11.2 | -15.3 | -45.3 | 49.2 | -1.6 | 7.3 |
Cash Flow from Investing Activities | -12.6 | -22.9 | -22.5 | -10.2 | -4.3 | -2.8 | -4.7 | -4.0 | -2.9 | 0.1 | 5.5 | -1.2 |
Cash Flow from Financing Activities | 37.3 | 39.5 | 37.7 | 28.6 | 17.3 | 9.3 | 15.8 | 13.2 | 54.1 | -49.3 | -4.1 | -6.1 |
Net Cash Inflow / Outflow | 0.0 | -0.6 | 0.5 | -17.1 | 16.9 | 0.3 | -0.2 | -6.0 | 6.0 | 0.0 | -0.1 | 0.1 |
Opening Cash & Cash Equivalents | 0.1 | 0.7 | 0.2 | 17.3 | 0.4 | 0.1 | 0.3 | 6.3 | 0.4 | 0.3 | 0.4 | 0.4 |
Closing Cash & Cash Equivalent | 0.1 | 0.1 | 0.7 | 0.2 | 17.3 | 0.4 | 0.1 | 0.3 | 6.3 | 0.4 | 0.3 | 0.4 |
The Industry PFCF Ratio stands at 37.30, vs the PFCF Ratio of -2.82, which results in a Negative aspect.
The Industry PCF RATIO stands at 26.82, vs the PCF RATIO of -4.92, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 129.8 | 148.9 | 105.8 | 114.6 | 90.9 | 209.4 | 106.4 | 191.6 | 218.1 | 119.8 | 67.6 | 158.6 | 95.8 | 166.9 | 115.7 | 147.5 |
Total Income | 130.1 | 150.6 | 106.2 | 116.5 | 91.1 | 212.2 | 107.7 | 199.5 | 220.1 | 121.1 | 67.9 | 163.0 | 96.3 | 167.7 | 116.2 | 148.5 |
Total Expenditure | 150.7 | 157.9 | 132.0 | 160.9 | 120.8 | 228.4 | 169.1 | 289.4 | 317.1 | 197.7 | 132.8 | 203.8 | 152.3 | 198.0 | 158.7 | 187.9 |
PBIDT (Excl OI) | -20.9 | -9.0 | -26.2 | -46.2 | -29.9 | -19.0 | -62.7 | -97.8 | -99.0 | -77.9 | -65.3 | -45.3 | -56.5 | -31.0 | -43.0 | -40.3 |
Other Income | 0.3 | 1.7 | 0.4 | 1.9 | 0.2 | 2.8 | 1.3 | 7.9 | 2.0 | 1.3 | 0.3 | 4.4 | 0.6 | 0.7 | 0.5 | 1.0 |
Operating Profit | -20.6 | -7.3 | -25.8 | -44.3 | -29.6 | -16.3 | -61.4 | -89.9 | -97.0 | -76.6 | -65.0 | -40.8 | -56.0 | -30.3 | -42.5 | -39.3 |
Interest | 11.9 | 11.3 | 11.0 | 10.3 | 9.0 | 7.4 | 3.0 | 2.8 | 18.2 | 17.8 | 15.1 | 14.9 | 14.3 | 21.3 | 12.3 | 9.9 |
Exceptional Items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PBDT | -32.5 | -18.6 | -36.8 | -54.6 | -38.6 | -23.7 | -64.4 | -92.7 | -115.3 | -94.3 | -80.1 | -55.7 | -70.2 | -51.5 | -54.8 | -49.3 |
Depreciation | 17.3 | 17.1 | 16.5 | 14.8 | 16.9 | 16.9 | 16.9 | 20.5 | 14.2 | 14.2 | 14.2 | 14.1 | 12.4 | 12.4 | 12.4 | 12.3 |
Profit Before Tax | -49.8 | -35.7 | -53.3 | -69.4 | -55.6 | -40.6 | -81.4 | -113.1 | -129.4 | -108.5 | -94.2 | -69.9 | -82.6 | -63.9 | -67.2 | -61.6 |
Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | -49.8 | -35.7 | -53.3 | -69.4 | -55.6 | -40.6 | -81.4 | -113.1 | -129.4 | -108.5 | -94.2 | -69.9 | -82.6 | -63.9 | -67.2 | -61.6 |
Net Profit | -49.8 | -35.7 | -53.3 | -69.4 | -55.6 | -40.6 | -81.4 | -113.1 | -129.4 | -108.5 | -94.2 | -69.9 | -82.6 | -63.9 | -67.2 | -61.6 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 215.6 | 215.6 | 215.6 | 215.6 | 215.6 | 215.6 | 215.6 | 215.6 | 215.6 | 215.6 | 215.6 | 196.2 | 196.2 | 196.2 | 196.2 | 180.0 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | -2.3 | -1.7 | -2.5 | -3.1 | -2.6 | -1.9 | -3.8 | -5.4 | -6.0 | -5.1 | -4.4 | -3.5 | -4.2 | -3.3 | -3.4 | -3.5 |
Operating Profit Margin | -15.9 | -4.9 | -24.4 | -38.7 | -32.6 | -7.8 | -57.7 | -46.9 | -44.5 | -63.9 | -96.2 | -25.7 | -58.4 | -18.1 | -36.8 | -26.7 |
Net Profit Margin | -38.4 | -24.0 | -50.4 | -60.5 | -61.1 | -19.4 | -76.5 | -59.1 | -59.3 | -90.6 | -139.5 | -44.1 | -86.2 | -38.3 | -58.1 | -41.7 |
The Industry Net Sales Growth stands at 9.94, vs the Net Sales Growth of -12.68, which results in a Negative aspect.
The Industry Mcap Growth stands at -4.55, vs the Mcap Growth of -60.67, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 79.00 | 81.75 | 74.65 |
R3 | 77.33 | 77.50 | 73.83 |
R2 | 75.67 | 75.75 | 73.55 |
R1 | 74.33 | 74.50 | 73.28 |
Pivot | 72.67 | 72.75 | 72.67 |
S1 | 71.33 | 71.50 | 72.73 |
S2 | 69.67 | 69.75 | 72.45 |
S3 | 68.33 | 68.50 | 72.18 |
S4 | 67.00 | 63.75 | 71.35 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
56.69
Neutral
RSI
52.14
Neutral
ROC
1.55
Bullish
UltimateOscillator
57.25
Neutral
Williams Indicator
-33.90
Neutral
CCI Indicator
59.30
Neutral
MACD
-2,865.94
Bearish
Stochastic Indicator
71.02
Neutral
ATR
3.85
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|
Date Of Conduct | Board Meeting Details |
---|---|
12-02-2024 | Quarterly Results |
08-11-2023 | Quarterly Results |
09-08-2023 | Quarterly Results |
24-05-2023 | Audited Results |
03-02-2023 | Quarterly Results |
10-11-2022 | Quarterly Results |
01-08-2022 | Quarterly Results & Inter alia, to consider the following: 1. To consider and approve the un-audited financial results along with the Limited review Report for the quarter ended 30th June, 2022. 2. Any other matter with the permission of the Chair. |
23-05-2022 | Audited Results |
12-02-2022 | Quarterly Results |
09-11-2021 | Quarterly Results |
22-10-2021 | Preferential Issue of shares & Increase in Authorised Capital |
30-07-2021 | Quarterly Results |
27-05-2021 | Audited Results |